A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis

Sang-A Choi, Seung‐Geun Lee, Sang Heon Song, Ji‐Min Kim, Hye-Yoon Jang, Woo‐Jin Jung, Jonghyun Choi, Young Eun Park, Seong-Hu Park, Joung‐Wook Lee, Jun‐Hee Lee, Seung-Hoon Baek, Geun-Tae KimJournal of Rheumatic Diseases 2013 · DOI

Abstract

Treatments for patients with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and anti-tumor necrosis factor-alpha (TNF) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNF agents in patients with end-stage renal disease, especially those receiving peritoneal dialysis (PD), have not been investigated well, little is known about treating them with anti-TNF agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.

Introduction

Ankylosing Spondylitis (AS) is a chronic inflammatory condition that primarily affects the spine and joints, often leading to severe pain and disability. Management typically relies on non-steroidal anti-inflammatory drugs (NSAIDs) and certain disease-modifying antirheumatic drugs (DMARDs) like sulfasalazine. However, these first-line treatments are notoriously nephrotoxic, making them unsuitable for patients with impaired kidney function or end-stage renal disease (ESRD).

While newer anti-tumor necrosis factor-alpha (anti-TNF-$α$) agents like etanercept have revolutionized AS care, clinical data regarding their use in patients undergoing peritoneal dialysis (PD) is scarce. Because the pharmacokinetics and safety profiles in this specific population are under-researched, clinicians often lack the data needed to prescribe these biologics safely. This case study evaluates the safety and efficacy of etanercept in a patient with AS receiving PD.

Methods

The researchers conducted a longitudinal clinical case study of a 40-year-old male patient with a dual diagnosis of AS and IgA nephropathy. The patient had been on peritoneal dialysis for three years and suffered from high disease activity despite previous treatments.

The intervention involved the subcutaneous administration of 25 mg of etanercept twice weekly. The team monitored the patient over a nine-month period, measuring clinical symptoms and laboratory markers at baseline, three months, and nine months. Standardized rheumatology tools were utilized, including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), and the Ankylosing Spondylitis Disease Activity Score (ASDAS).

Results

The patient showed dramatic improvement across all clinical and inflammatory markers without compromising renal function. As shown in Table 1, the BASDAI score dropped from a severe 7.7 at baseline to 1.2 at nine months, indicating near-remission. Objective inflammatory markers also plummeted: C-reactive protein (CRP) levels fell from 19.4 mg/dL to 2.3 mg/dL, and the erythrocyte sedimentation rate (ESR) decreased from 120 mm/hr to 59 mm/hr.

Critically, markers of renal function remained stable throughout the study. Blood Urea Nitrogen (BUN) and serum creatinine levels showed no significant deviation from the patient's dialysis baseline, suggesting that etanercept did not negatively impact residual renal function or interfere with the dialysis process.

Table 1: Clinical and laboratory markers at baseline, 3 months, and 9 months of etanercept treatment.

Discussion

This case provides rare longitudinal evidence that etanercept can be both safe and highly effective for treating AS in patients on peritoneal dialysis. By using the ASDAS (which incorporates CRP levels) alongside the patient-reported BASDAI, the authors demonstrated a "major improvement" in disease activity according to Assessment of SpondyloArthritis international Society (ASAS) criteria. Symptoms such as inflammatory back pain, peripheral arthritis, and dactylitis all resolved or significantly improved.

While these results are encouraging, the primary limitation is the single-patient sample size ($N=1$). A single case report cannot definitively establish a safety protocol for all PD patients. Longer-term studies and larger-scale research are needed to formally assess the pharmacokinetics of anti-TNF agents in the ESRD population to move beyond case-by-case clinical intuition.

Summary updated

Abstract

Treatments for patient with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (TNF) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNF agents in patients of end stage renal disease, especially those receiving peritoneal di-alysis (PD), have not been investigated well, little is known about treating them with anti-TNF agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.
BibTeX
@article{choi2013case,
  author = {Sang-A Choi and Seung‐Geun Lee and Sang Heon Song and Ji‐Min Kim and Hye-Yoon Jang and Woo‐Jin Jung and Jonghyun Choi and Young Eun Park and Seong-Hu Park and Joung‐Wook Lee and Jun‐Hee Lee and Seung-Hoon Baek and Geun-Tae Kim},
  title = {{A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis}},
  journal = {Journal of Rheumatic Diseases},
  year = {2013},
  doi = {10.4078/jrd.2013.20.6.361},
}
Figure